Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

10/4/2005 12:09:39 PM ET

SWISS MEDICA TO PRESENT TO INSTITUTIONAL INVESTORS IN EUROPE

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

October 4, 2005

SWISS MEDICA TO PRESENT TO INSTITUTIONAL INVESTORS IN EUROPE

Toronto, Canada - Swiss Medica, Inc. (OTCBB: SWME) today announced that Chief Executive Officer, Raghu

Kilambi will be making presentations to institutional investors on Swiss Medica and speaking at biotech

investment conferences between October 4 and October 12th in Zurich, Cadaques (Spain), Paris, Brussels and

London.

Mr. Kilambi will present Swiss Medica on October 4-5th at the 5th Annual Biotech in Europe Investor Forum in

Zurich, co-sponsored by Sachs Associates and Bloomberg LLP. In addition, Mr. Kilambi will present Swiss Medica

on October 7-8th, 2005 at the invitation only Theime Small Cap Conference in Spain. The Thieme small cap

conference showcases 6 carefully selected companies the Nanotechnology, Biotech and Energy fields.

Investors and analysts can view Swiss Medica’s latest corporate and investor brochure at www.swissmedica.com.

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a

world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com,

and

Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain

relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by

healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available

throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit

, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS

Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce

changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:

www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United

States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

For more information, please contact:

Swiss Medica Inc.

Investor Relations Contact:

David Jones

(866) 485-4243